Yuji Matsuda

Yuji Matsuda

Auto-generated profile, based on publicly available information

Yuji Matsuda

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in European Heart Journal
Verified
Journal Article
Closed access
DGDaniele Giacoppo
Daniele Giacoppo
YMYuji Matsuda
Yuji Matsuda
LFLuca Nai Fovino
Luca Nai Fovino
GDGianpiero D’aMico
Gianpiero D’aMico
Giuseppe GargiuloGiuseppe Gargiulo
Giuseppe Gargiulo
GTGiuseppe Tarantini
Giuseppe Tarantini
Aims: After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) with a P2Y12 receptor inhibitor confers benefits compared with prolonged DAPT is unclear. Methods and results: Multiple electronic databases, including PubMed, Scopus, Web of Sciences, Ovid, and ScienceDirect, were searched to identify randomized clinical trials comparing ≤3 months of DAPT followed by P2Y12 inhibitor SAPT vs. 12 months of DAPT after PCI with second-generation DES implantation. The primary and co-primary outcomes of interest were major bleeding and stent thrombosis 1 year after randomization. Summary hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by fixed-effect and random-effects models. Multiple sensitivity analyses including random-effects models 95% CI adjustment were applied. A sensitivity analysis comparing trials using P2Y12 inhibitor SAPT with those using aspirin SAPT was performed. A total of five randomized clinical trials (32 145 patients) were available. Major bleeding was significantly lower in the patients assigned to short DAPT followed by P2Y12 inhibitor SAPT compared with those assigned to 12-month DAPT (random-effects model: HR 0.63, 95% 0.45–0.86). No significant differences between groups were observed in terms of stent thrombosis (random-effects model: HR 1.19, 95% CI 0.86–1.65) and the secondary endpoints of all-cause death (random-effects model: HR 0.85, 95% CI 0.70–1.03), myocardial infarction (random-effects model: HR 1.05, 95% CI 0.89–1.23), and stroke (random-effects model: HR 1.08, 95% CI 0.68–1.74). Sensitivity analyses showed overall consistent results. By comparing trials testing ≤3 months of DAPT followed by P2Y12 inhibitor SAPT vs. 12 months of DAPT with trials testing ≤3 months of DAPT followed by aspirin SAPT vs. 12-month of DAPT, there was no treatment-by-subgroup interaction for each endpoint. By combining all these trials, regardless of the type of SAPT, short DAPT was associated with lower major bleeding (random-effects model: HR 0.63, 95% CI 0.48–0.83) and no differences in stent thrombosis, all-cause death, myocardial infarction, and stroke were observed between regimens. Conclusion: After second-generation DES implantation, 1–3 months of DAPT followed by P2Y12 inhibitor SAPT is associated with lower major bleeding and similar stent thrombosis, all-cause death, myocardial infarction, and stroke compared with prolonged DAPT. Whether P2Y12 inhibitor SAPT is preferable to aspirin SAPT needs further investigation.

7 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LFLuca Nai Fovino
Luca Nai Fovino
Andrea ScottiAndrea Scotti
Andrea Scotti
MMMauro Massussi
Mauro Massussi
FCFrancesco Cardaioli
Francesco Cardaioli
GRGiulio Rodinò
Giulio Rodinò
GTGiuseppe Tarantini
Giuseppe Tarantini
Background: Transcatheter aortic valve replacement (TAVR)‐in‐TAVR is a possible treatment for transcatheter heart valve ( THV ) degeneration. However, the displaced leaflets of the first THV will create a risk plane ( RP ) under which the passage of a coronary catheter will be impossible. The aim of our study was to evaluate the potential risk of impaired coronary access ( CA ) after TAVR ‐in‐ TAVR . Methods and Results: We prospectively performed coronary angiography after TAVR with different THV s in 137 consecutive patients, looking where the catheter crossed the valve frame. If coronary cannulation was achieved from below the RP , the distance between valve frame and aortic wall was measured by aortic angiography. CA after TAVR ‐in‐ TAVR was defined as feasible if the catheter passed above the RP , as theoretically feasible if passed under the RP with valve‐to‐aorta distance >2 mm, and as unfeasible if passed under the RP with valve‐to‐aorta distance ≤2 mm. Seventy‐two patients (53%) received a Sapien 3 THV, 26 (19%) received an Evolut Pro/R THV, and 39 (28%) received an Acurate Neo THV . CA after TAVR ‐in‐ TAVR was considered feasible in 40.9% (68.1%, 19.2%, and 5.1%, respectively; P <0.001), theoretically feasible in 27.7% (8.3%, 42.3%, and 53.8%, respectively; P <0.001), and unfeasible in 31.4% (23.6%, 38.5%, and 41.1%, respectively; P =0.116). Independent predictors of impaired CA after TAVR ‐in‐ TAVR were female sex (odds ratio [OR], 3.99; 95% CI , 1.07–14.86; P =0.040), sinotubular junction diameter (OR, 0.62; 95% CI , 0.48–0.80; P <0.001), and implantation of a supra‐annular THV (OR, 6.61; 95% CI , 1.98–22.03; P =0.002). Conclusions: CA after TAVR ‐in‐ TAVR might be unfeasible in >30% of patients currently treated with TAVR . Patients with a small sinotubular junction and those who received a supra‐annular THV are at highest risk of potential CA impairment with TAVR ‐in‐ TAVR .

8 January 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
LFLuca Nai Fovino
Luca Nai Fovino
Andrea ScottiAndrea Scotti
Andrea Scotti
MMMauro Massussi
Mauro Massussi
TFTommaso Fabris
Tommaso Fabris
FCFrancesco Cardaioli
Francesco Cardaioli
GTGiuseppe Tarantini
Giuseppe Tarantini

20 May 2019 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
TYTakanobu Yamamoto
Takanobu Yamamoto
SYSawako Yada
Sawako Yada
YMYuji Matsuda
Yuji Matsuda
HOHirofumi Otani
Hirofumi Otani
SYShunji Yoshikawa
Shunji Yoshikawa
TATakashi Ashikaga
Takashi Ashikaga
Background. While the evaluation of burr speed was discussed regarding platelet aggregation, the association between platform speed and acute lumen gain of rotational atherectomy remains unknown. Methods. Through the evaluation of the potential of low-speed rotational atherectomy (LSRA) in in-vitro experiments, minimum lumen diameter (MLD) and minimum lumen area (MLA) after conventional high-speed rotational atherectomy (HSRA group) and those after LSRA following HSRA (LSRA+HSRA group) treated by 1.5 mm burrs were measured by optical frequency domain imaging (OFDI) in 30 consecutive human lesions. Results. The in-vitro experiments demonstrated that MLD and MLA after LSRA+HSRA were significantly larger (MLD: LSRA+HSRA=1.50 ±0.05 mm, HSRA= 1.43 ±0.05 mm, p=0.015; MLA: LSRA+HSRA= 1.90 ±0.17 mm2, HSRA= 1.71±0.11 mm2, and p= 0.037), requiring more crossing attempts (LSRA= 134 ±20 times, HSRA= 72 ±11 times, and p< 0.001). In human studies, there was no significance in reference vessel diameter and lesion length before the procedure between two groups. MLDs after LSRA+HSRA were significantly larger than those in HSRA (LSRA+HSRA= 1.22 ±0.16 mm, HSRA= 1.07 ±0.14 mm, and p= 0.0078), while MLAs after LSRA+HSRA tended to be larger (LSRA+HSRA= 1.79 ±0.51 mm2, HSRA= 1.55 ±0.47 mm2, and p= 0.19). There was no significance in the occurrence of in-hospital complication, including slow flow or no reflow, major dissection, and procedural myocardial infarction, between LSRA+HSRA and HSRA. Conclusions. LSRA can achieve larger lumen gain compared, whereas HSRA can pass calcified lesions easily. Combination of LSRA and HSRA is a safe and feasible strategy for severely calcified lesions in clinical practice.

11 March 2016 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
MHMasahiro Hoshino
Masahiro Hoshino
TYTaishi Yonetsu
Taishi Yonetsu
AMAkira Mizukami
Akira Mizukami
YMYuji Matsuda
Yuji Matsuda
KYKenji Yoshioka
Kenji Yoshioka
YHYuji Hashimoto
Yuji Hashimoto

10 July 2018 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
PDF file
YMYuji Matsuda
Yuji Matsuda
TATakashi Ashikaga
Takashi Ashikaga
TSTaro Sasaoka
Taro Sasaoka
YHYu Hatano
Yu Hatano
TUTomoyuki Umemoto
Tomoyuki Umemoto
KHKenzo Hirao
Kenzo Hirao